Maricann Group (CNSX:MARI – Free Report) had its target price increased by Raymond James Financial from $6.50 to $11.50 in a research report released on Thursday,BayStreet.CA reports.
MARI has been the subject of a number of other research reports. National Bankshares upped their price target on Maricann Group from $7.50 to $11.00 and gave the stock an “outperform” rating in a report on Friday, July 4th. BMO Capital Markets upped their price target on Maricann Group from $7.00 to $9.50 and gave the stock an “outperform” rating in a report on Friday, July 4th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Maricann Group has an average rating of “Buy” and an average target price of $10.67.
Check Out Our Latest Analysis on Maricann Group
Maricann Group Price Performance
Maricann Group Company Profile
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Featured Articles
- Five stocks we like better than Maricann Group
- Ride Out The Recession With These Dividend Kings
- Equal Weight ETFs: Hidden Upside in Today’s Market
- How to Profit From Value Investing
- Zillow Group Approaching Key Technical Levels: Is It Time to Buy?
- What is the FTSE 100 index?
- For True Diversification: 3 Stocks You Can Buy Now
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
